Predicting clinical events characterizing the progression of amyotrophic lateral sclerosis via machine learning approaches using routine visits data: a feasibility study.
Source check: Source checked. Not independent scientific confirmation.
Finding: h The reviewed source supports this bounded result; external generalization, causal effects, and sustained operational impact remain unestablished where the source reports retrospective or internal evaluation.
Technology: Logistic-regression and MLP models learn from routine ALS registry visits to predict death, PEG and NIV clinical events; SHAP analyzes predictors.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Logistic-regression and MLP models learn from routine ALS registry visits to predict death, PEG and NIV clinical events; SHAP analyzes predictors.
- Test and result
- The feasibility study reports independent-test AUROC/AUPRC above 0.8 for several ALS progression outcomes, a specific clinical prediction result.
- Limitation / still unknown
- Independent test sets across three outcomes, plus SHAP and collinearity analyses, validate the retrospective feasibility claim.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s12911-024-02719-5
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.